Neurocrine Biosciences' (NBIX) NDA for INGREZZA Accepted by FDA; Priority Review Granted
Tweet Send to a Friend
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
